Clipping of news on Brazilian Culture, Law and Citizenship
09/10/2012
This article was translated by an automatic translation system, and was therefore not reviewed by people.
Interfarma monitored the time required for approval of the National Health Surveillance Agency (ANVISA) to release new drugs to the market for one year, from August 2011 to August 2012, based on data available in the system Datavisa.
The study showed that for new medications, that do not have generic or similar, the release time increased during the analysis period from seven months to one year and four months.
Biologic drugs, which can help in the treatment of complex diseases such as cancer and rheumatoid arthritis, the release may take over a year. The drugs are the generic or similar record holders in waiting time: may take up to two years to reach the market.
According to the study, the approval period for new drugs by ANVISA is long and historically has been progressively extended, which affect millions of people.
Factors such as the expansion of the Brazilian market and increased demand for medicines at the same time that Anvisa works with insufficient staff, contribute to this situation. However, bureaucracy is what most complicates the process of liberation.
Source: R7 News
Our news are removed entirely from the sites of our partners. For this reason, we can not change their content even in cases of typos.
This article was translated by an automatic translation system, and was therefore not reviewed by people.